Key result
FGB-455 'A' allele carriers had lower risks of stroke, mortality, and ESRD when treated with lisinopril versus amlodipine or chlorthalidone, compared to 'GG' homozygotes (interaction P≤0.04).
Why the study?
Does lisinopril improve outcomes in hypertensive patients with the FGB-455 minor 'A' allele compared to amlodipine or chlorthalidone?
RCT (n=30,076)
Does lisinopril improve outcomes in hypertensive patients with the FGB-455 minor 'A' allele compared to amlodipine or chlorthalidone?
Carriers of the FGB-455 minor 'A' allele may derive greater benefit from lisinopril compared to amlodipine or chlorthalidone for reducing stroke, mortality, and ESRD.
No takes yet. Share an insight, caveat, or question.
May support lisinopril preference in FGB-455 A carriers; hypothesis-generating and requires randomized confirmation before practice change.
Lynch et al. (2009) conducted an RCT in Hypertension (n=30,076). Lisinopril vs. Amlodipine or chlorthalidone was evaluated on Coronary heart disease (fatal coronary heart disease or non-fatal myocardial infarction). FGB-455 'A' allele carriers had lower risks of stroke, mortality, and ESRD when treated with lisinopril versus amlodipine or chlorthalidone, compared to 'GG' homozygotes (interaction P≤0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: